Sök artiklar i SveMed+

Tidskrift

Sammanfattning

As a common pharmaceutical compound for the prevention of stroke, dipyridamole (DP) 200mg/acetylsalicylic acid (ASA) 25mg (Asasantin®), is accompanied with initial unwanted side effects, we performed a randomised, 10 day, open-label, and blinded follow-up study on 30 stroke patients, consecutively recruited within 10 days after stroke in order to evaluate the tolerance of two different treatment regimes. Half of the patients had ordinary full dose medication DP 200 mg/ASA 25 mg twice daily from start (F-group) and the other group had half ordinary dose during 5 days to eventually receive full dose (T-group). A patient diary recording frequency, type, and grade of side effects together with pain relief treatment was filled in on a daily basis by an independent nurse. There was a difference in the incidence of side effects between the F- and T-group (6 patients vs 2;X2=2,727:p=0.09). Headache was the most common side effect in both groups with a significant difference in incidence with 40 % in the F-group compared to 6 % in the T-group (6 patients vs 1; X2=4,658:p<0,05). Generally headache was graded more severe in the F-group than the Tgroup. Medication compliance in the T-group was total while 2 patients (12 %) stopped and 1 patient needed titrating regime in the F-group. The results of this study suggest that a 5 day low dose initial treatment with a common pharmacological secondary stroke preventive compound, DP 200mg/ ASA 25mg (Asasantin®), decreases side effects and their severity together with no drop-outs and a total compliance of medication. Followingly, by minimizing side effects more patients are able to use this medication and the pharmacological prerequisites of stroke prevention are optimised.

MeSH